SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today publishes the Annual Report for the financial year 2025. The Annual Report is attached to this press release and available on the company’s website www.synactpharma.com.
The annual report is published in Swedish and English. The Swedish annual report is also available on SynAct's website in European Single Electronic Format (ESEF).